-
12:21:59 PM

ACAD Stock News

03/10/23 9:45 PM
Nasdaq : ACAD
fda approval
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
Acadia Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved DAYBUE™ for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. “Rett syndrome is a profoundly debilitating and complex, rare, neurodevelopmental disorder that presents differently across patients and can lead to an...
RHEA-AI
neutral
02/27/23 4:05 PM
Nasdaq : ACAD
earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc., today announced its financial results for the fourth quarter and full year ended December 31, 2022. NUPLAZID ® delivered net sales of $136.5 million in the fourth quarter of 2022 and $517.2 million for the full year. Both of these analyses found a lower mortality risk in patients with Parkinson’ s disease psychosis treated with...
RHEA-AI
neutral
02/14/23 4:05 PM
Nasdaq : ACAD
earnings
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
Acadia Pharmaceuticals Inc. today announced that it will report fourth quarter and full year 2022 financial results on Monday, February 27, 2023, after the close of the U.S. financial markets. Acadia’ s management team will also host a conference call and webcast on February 27, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.
RHEA-AI
neutral
01/03/23 9:00 AM
Nasdaq : ACAD
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
Acadia Pharmaceuticals Inc. announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’ s disease psychosis treated with NUPLAZID ® compared to other atypical antipsychotics over 12 months and across various subgroups. The robust results were achieved across...
RHEA-AI
neutral
12/21/22 4:05 PM
Nasdaq : ACAD
conferences
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Acadia Pharmaceuticals Inc. today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session. Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson 395-3043 media@acadia-pharm.com. Investor Contact: Acadia Pharmaceuticals Inc....
RHEA-AI
neutral
10/27/22 4:05 PM
Nasdaq : ACAD
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
Acadia Pharmaceuticals Inc. today announced that its President, Srdjan Stankovic, M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will retire at the end of the year. A search for a successor to Dr. Stankovic is ongoing. Following his retirement, Dr. Stankovic will provide consulting and advisory services for Acadia on a part-time...
RHEA-AI
very positive